The development of CAR T cells targeting the CD19 antigen resulted in a remission rate of close to 90% in r/r B-ALL, and 30–50% in chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma in a phase I clinical trial. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.